LLY

1,142.47

+1.34%↑

JNJ

234.86

+2.94%↑

ABBV

229.14

+2.6%↑

UNH

400.05

+1.05%↑

MRK

121.94

+1.97%↑

LLY

1,142.47

+1.34%↑

JNJ

234.86

+2.94%↑

ABBV

229.14

+2.6%↑

UNH

400.05

+1.05%↑

MRK

121.94

+1.97%↑

LLY

1,142.47

+1.34%↑

JNJ

234.86

+2.94%↑

ABBV

229.14

+2.6%↑

UNH

400.05

+1.05%↑

MRK

121.94

+1.97%↑

LLY

1,142.47

+1.34%↑

JNJ

234.86

+2.94%↑

ABBV

229.14

+2.6%↑

UNH

400.05

+1.05%↑

MRK

121.94

+1.97%↑

LLY

1,142.47

+1.34%↑

JNJ

234.86

+2.94%↑

ABBV

229.14

+2.6%↑

UNH

400.05

+1.05%↑

MRK

121.94

+1.97%↑

Home・Lista de Ações・MannKind Corp

MannKind Corp

Abrir

SetorSaúde

3.41 -2.01

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.4

Máximo

3.52

Indicadores-chave
By Trading Economics
Rendimento	-671K -17M
Vendas	-22M 90M
P/E Médio do Setor	140.5 49.888
EPS	-0.02
Margem de lucro	-18.431
Funcionários	591
EBITDA	5.9M 3.4M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+131.53% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	223M 1.1B
Abertura anterior	5.42
Fecho anterior	3.41

Sentimento de Notícias

By Acuity

47%

53%

150 / 344 Ranking em Healthcare

MannKind Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de jun. de 2026, 21:51 UTC

Grandes Movimentos do Mercado

Merlin Shares Rally After Defense Department's Design Review Wraps

4 de jun. de 2026, 23:46 UTC

Conversa de Mercado

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 de jun. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 de jun. de 2026, 23:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 de jun. de 2026, 23:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Energy Resources of Australia to Enter Trading Halt

4 de jun. de 2026, 23:34 UTC

Conversa de Mercado

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 de jun. de 2026, 23:31 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 de jun. de 2026, 23:31 UTC

Conversa de Mercado

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 de jun. de 2026, 23:31 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

4 de jun. de 2026, 23:08 UTC

Conversa de Mercado

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 de jun. de 2026, 22:41 UTC

Conversa de Mercado

Australia Shares Set to Rise at the Open -- Market Talk

4 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

4 de jun. de 2026, 20:44 UTC

Aquisições, Fusões, Aquisições de Empresas

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 de jun. de 2026, 20:16 UTC

Conversa de Mercado

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 de jun. de 2026, 20:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 de jun. de 2026, 19:46 UTC

Conversa de Mercado

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 de jun. de 2026, 19:38 UTC

Conversa de Mercado

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 de jun. de 2026, 19:30 UTC

Conversa de Mercado

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 de jun. de 2026, 18:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 de jun. de 2026, 18:38 UTC

Ganhos

Money Quote: Tech Weakness in Context -- WSJ

4 de jun. de 2026, 18:24 UTC

Ganhos

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 de jun. de 2026, 17:09 UTC

Conversa de Mercado

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 de jun. de 2026, 16:58 UTC

Ganhos

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 de jun. de 2026, 16:46 UTC

Conversa de Mercado

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 de jun. de 2026, 16:38 UTC

Ganhos

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

4 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

4 de jun. de 2026, 16:13 UTC

Conversa de Mercado

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 de jun. de 2026, 16:11 UTC

Conversa de Mercado

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 de jun. de 2026, 15:56 UTC

Conversa de Mercado

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparação entre Pares

Variação de preço

MannKind Corp Previsão

Preço-alvo

By TipRanks

131.53% parte superior

Previsão para 12 meses

Média 8.15 USD 131.53%

Máximo 11 USD

Mínimo 4.75 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para MannKind Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

Comprar

Manter

Vender

Com base em 6 analistas que deram avaliações de ações para MannKind Corp - Dist nos últimos 3 meses.

Sentimento

By Acuity

150 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.